ClinicalTrials.gg

TargetBeta

CD3E

CD3 epsilon subunit of T-cell receptor complex · also CD3epsilon, CD3-epsilon · CD molecules

84 programs in company-led studies act on CD3E, from 49 companies: 24 in phase 3, 5 approved with new studies. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (60 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
linvoseltamabruleRegeneron Pharmaceuticalsphase 41312 runningTNFRSF17NCIt
teclistamabruleJohnson & Johnsonphase 41110 runningTNFRSF17NCIt
elranatamabrulePfizerphase 4159 runningTNFRSF17NCIt
blinatumomabruleAmgenphase 4297 runningCD19ChEMBL
teplizumabruleSanofiphase 492 running–ChEMBL
epcoritamabruleGenmabphase 31312 runningMS4A1ChEMBL
tarlatamabruleAmgenphase 31312 runningDLL3ChEMBL
AlveltamigruleSuzhou Zelgen Biopharmaceuticalsphase 31111 runningDLL3NCIt
etentamigAbbViephase 31111 runningTNFRSF17the company's pipeline
obrixtamigBoehringer Ingelheimphase 31111 runningDLL3the company's pipeline
surovatamigAstraZenecaphase 31010 runningCD19a judged reading
glofitamabruleHoffmann-La Rochephase 3139 runningMS4A1ChEMBL
Anti-CD19/CD3 Bispecific Antibody MK-1045Merckphase 388 runningCD19a judged reading
mosunetuzumabruleHoffmann-La Rochephase 3147 runningMS4A1ChEMBL
cevostamabHoffmann-La Rochephase 387 runningFCRL5a judged reading
ramantamigJohnson & Johnsonphase 377 runningGPRC5D, TNFRSF17a judged reading
xaluritamigruleAmgenphase 377 runningSTEAP1NCIt
odronextamabruleRegeneron Pharmaceuticalsphase 386 runningMS4A1ChEMBL
GR1803ruleChongqing Genrix Biopharmaceuticalphase 376 running–the studies' text
Anti-Claudin18.2/Anti-CD3 Bispecific Antibody QLS31905ruleQilu Pharmaceuticalphase 365 runningCLDN18NCIt
CM336ruleKeymed Biosciencesphase 355 running–the studies' text
pasritamigJohnson & Johnsonphase 355 runningKLK2a judged reading
TQB2825Sino Biopharmaceuticalphase 354 runningMS4A1the company's pipeline
Anti-CD3/Anti-BCMA Bispecific Antibody TQB2934Sino Biopharmaceuticalphase 344 runningTNFRSF17the company's pipeline
gocatamigMerckphase 344 runningDLL3a judged reading
GPRC5D/BCMA/CD3-targeting T-cell Engager IBI3003ruleInnovent Biologicsphase 344 runningGPRC5D, TNFRSF17NCIt
emaretamigruleAstellas Pharmaphase 333 runningCLDN18NCIt
QLS4131ruleQilu Pharmaceuticalphase 333 runningGPRC5Dthe studies' text
QLS32015ruleQilu Pharmaceuticalphase 322 runningGPRC5Dthe studies' text
YK012ruleExcyte Biopharmaphase 255 runningCD19the studies' text
cizutamigruleUCBphase 252 runningTNFRSF17NCIt
vonsetamigruleRegeneron Pharmaceuticalsphase 232 runningTNFRSF17NCIt
Anti-BCMA/CD38/CD3 Trispecific Antibody ABBV-2001AbbViephase 222 runningCD38, TNFRSF17the company's pipeline
Anti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492AstraZenecaphase 222 runningCD8A, MS4A1a judged reading
Anti-FLT3/CD3 Bispecific Antibody CLN-049ruleCullinan Therapeuticsphase 222 runningFLT3NCIt
Anti-ROR1/Anti-CD3 Bispecific Antibody EMB-07ruleShanghai EpimAb Biotherapeuticsphase 222 runningROR1NCIt
GSK5926371GlaxoSmithKlinephase 222 runningCD19, MS4A1the company's pipeline
olsutamigruleRegeneron Pharmaceuticalsphase 222 runningFOLH1NCIt
YKST02ruleExcyte Biopharmaphase 222 running–the studies' text
foralumabruleTiziana Life Sciencesphase 281 running–NCIt
Anti-Claudin18.2/Anti-CD3 Bispecific Antibody AZD5863AstraZenecaphase 211 runningCLDN18a judged reading
Anti-GPC3 T Cell-engaging Antibody AZD9793AstraZenecaphase 211 runningCD8A, GPC3a judged reading
Anti-PSMA/Anti-CD3 T-cell Engager GSK5458514ruleGlaxoSmithKlinephase 211 runningFOLH1NCIt
Anti-STEAP2/Anti-CD3/Anti-CD8 Trispecific Antibody AZD6621AstraZenecaphase 211 runningCD8A, STEAP2a judged reading
MBS314 for InjectionruleBeijing Mabworks Biotechphase 211 runningGPRC5Dthe studies' text
REGN17372ruleRegeneron Pharmaceuticalsphase 211 runningCD28, GPRC5Dthe studies' text
REGN9220ruleRegeneron Pharmaceuticalsphase 211 runningCD22, MS4A1the studies' text
SHR-7787Jiangsu HengRui Medicinephase 211 runningDLL3the company's pipeline
SOA101ruleShine-On Biomedicalphase 211 running–the studies' text
VG712ruleVirogen Biotechnologyphase 211 running–the studies' text
VTRU200ruleVitruviaephase 211 running–the studies' text
Anti-CD19/Anti-CD3/Anti-CD28 Trispecific Antibody CC312ruleCytoCaresphase 144 runningCD19, CD28NCIt
Anti-CD19/CD3 T-cell Engaging Bispecific Antibody CLN-978ruleCullinan Therapeuticsphase 143 runningCD19NCIt
Anti-CD19/Anti-CD3/Anti-CD2 Trispecific Antibody PIT565Novartisphase 133 runningCD19, CD2the company's pipeline
Anti-CD79b/CD20/CD3 Trispecific Antibody JNJ-80948543ruleJohnson & Johnsonphase 133 runningMS4A1NCIt
Anti-CLDN6/CD3 Bispecific Antibody XmAb541ruleXencorphase 122 runningCLDN6NCIt
OM336ruleLakefront Biotherapeutics NVphase 122 running–the studies' text
Anti-TMEFF2/Anti-CD3 Bispecific Antibody JNJ-70218902ruleJohnson & Johnsonphase 121 runningTMEFF2NCIt
clesitamigHoffmann-La Rochephase 121 runningDLL3, TNFRSF9a judged reading
Anti-B7-H7/Anti-CD3 Bispecific Antibody NPX372ruleNextPoint Therapeuticsphase 111 runningHHLA2NCIt
Anti-BAFF-R/Anti-CD3 Bispecific Antibody LY4152199ruleEli Lillyphase 111 runningTNFRSF13CNCIt
Anti-CALRmut/Anti-CD3 Bispecific Antibody JNJ-88549968Johnson & Johnsonphase 111 runningCALRa judged reading
Anti-CD24/Anti-CD3 Bispecific Antibody ONC-783ruleOncoC4phase 111 runningCD24NCIt
Anti-CD70/CD3 Bispecific Antibody INCA036873ruleIncytephase 111 runningCD70NCIt
Anti-CG1/Anti-CD3 Bispecific T-cell Engager CBX-250ruleCrossbow Therapeuticsphase 111 running–NCIt
Anti-CLDN6/Anti-CD3 Bispecific Antibody BGB-B455ruleBeOne Medicinesphase 111 runningCLDN6NCIt
Anti-ENPP3/Anti-CD3 Bispecific Antibody JNJ-87890387Johnson & Johnsonphase 111 runningENPP3a judged reading
Anti-FRa/Anti-CD3 Bispecific TCE NTB-928ruleTeneoSevenphase 111 runningFOLR1NCIt
Anti-HLA-A*02:01/p53 R175H Bispecific T-cell Engager CLSP-1025ruleClasp Therapeuticsphase 111 runningTP53NCIt
Anti-LY6G6D/Anti-CD3 T-cell Engager CBI-1214ruleCartography Biosciencesphase 111 runningLY6G6DNCIt
Anti-mutCALR/Anti-CD3 Bispecific Antibody INCA035784ruleIncytephase 111 running–NCIt
Anti-PSMA/Anti-CD3 Dual-masked T-cell Engager JANX014ruleJanux Therapeuticsphase 111 runningFOLH1NCIt
Anti-TERT/Anti-CD3 T-cell Engager CBX-663ruleCrossbow Therapeuticsphase 111 runningTERTNCIt
Anti-ULBP2/5/6/CD3/CD2 Trispecific T-cell Engager EVOLVE104ruleEvolveImmune Unitedphase 111 runningCD2, RAET1G, ULBP2NCIt
ATG-201ruleAntengene Biologicsphase 111 runningCD19the studies' text
EMB-15ruleShanghai EpimAb Biotherapeuticsphase 111 runningALPG, ALPPthe studies' text
HLX3901Fosun Pharmaphase 111 runningCD28, DLL3the company's pipeline
HLX3902Fosun Pharmaphase 111 runningCD28, STEAP1the company's pipeline
KGX105ruleKangabio AUSTRALIA LTD PTYphase 111 runningEGFRthe studies' text
KT501ruleKali Therapeuticsphase 111 runningCD19the studies' text
KT502ruleKali Therapeuticsphase 111 runningCD19the studies' text
LVV Expressing VSV Glycoprotein/Anti-CD3 scFv Containing Transgene Encoding for Anti-BCMA CAR KLN-1010ruleKelonia Therapeuticsphase 111 runningTNFRSF17NCIt
TQB2029Sino Biopharmaceuticalphase 111 runningGPRC5Dthe company's pipeline
Anti-B7-H6/Anti-CD3 Bispecific Antibody BI 765049ruleBoehringer Ingelheimphase 130 runningNCR3LG1NCIt

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.